HFS
AVDL

Hantz Financial Services’s Avadel Pharmaceuticals AVDL Stock Holding History

Hantz Financial Services’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-785
Closed -$13K – 1067
2024
Q1 		$13K Hold
785
– – ﹤0.01% 795
2023
Q4 		$11K Hold
785
– – ﹤0.01% 787
2023
Q3 		$8K Hold
785
– – ﹤0.01% 823
2023
Q2 		$13K Hold
785
– – ﹤0.01% 748
2023
Q1 		$7K Buy
+785
New +$6.45K ﹤0.01% 830

Other funds holding AVDL

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hantz Financial Services's AVDL Position: Q2 2024 in Review

Hantz Financial Services sold out of Avadel Pharmaceuticals (AVDL) in Q2 2024, closing a stake of 785 shares — an estimated $13K sold.

Hantz Financial Services first reported a position in AVDL in Q1 2023 and held it in 5 quarters. The position peaked at $13K in Q1 2024. 155 funds tracked by Wall St. Rank hold AVDL as of Q2 2024.

  • Hantz Financial Services reported no remaining Avadel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Hantz Financial Services sold 785 Avadel Pharmaceuticals shares in Q2 2024, an estimated $13K.
  • Hantz Financial Services first reported a position in Avadel Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Hantz Financial Services's Avadel Pharmaceuticals position peaked at $13K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2024.

Based on Hantz Financial Services's 13F filing for Q2 2024, filed 30 Jul 2024.